Immunic, Inc. (IMUX)
| Market Cap | 343.51M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -40.55M |
| Shares Out | 18.41M |
| EPS (ttm) | -3.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 24 |
| Last Price | $16.39 |
| Previous Close | $16.58 |
| Change ($) | -0.19 |
| Change (%) | -1.15% |
| Day's Open | 16.76 |
| Day's Range | 16.16 - 16.98 |
| Day's Volume | 198,691 |
| 52-Week Range | 4.19 - 28.21 |
Immunic Inc (NASDAQ: IMUX) has announced top-line data from an investigator-sponsored Phase 2 proof-of-concept trial evaluating IMU-838 in primary sclerosing cholangitis (PSC), a rare liver di...
NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating ...
Immunic Inc (NASDAQ: IMUX) completes the main analysis of Phase 1 CALVID-1 trial evaluating its lead asset, IMU-838. It is a selective oral DHODH inhibitor used in hospitalized patients with m...
NEW YORK, Feb. 17, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating ...
NEW YORK, Feb. 11, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating ...
NEW YORK, Jan. 5, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating c...
NEW YORK, Dec. 14, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating ...
NEW YORK, Nov. 24, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating ...
NEW YORK, Nov. 17, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating ...
NEW YORK, Nov. 10, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating ...
NEW YORK, Nov. 2, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating c...
LUXEMBOURG and GRÄFELFING, Germany and NEW YORK, Oct. 20, 2020 /PRNewswire/ -- The European Investment Bank (EIB) and Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company d...
NEW YORK, Sept. 29, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating...
NEW YORK, Sept. 28, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating...
NEW YORK, Sept. 11, 2020 /PRNewswire/ -- Immunic, Inc.
NEW YORK, Sept. 8, 2020 /PRNewswire/ -- Immunic, Inc.
NEW YORK, Aug. 20, 2020 /PRNewswire/ -- Immunic, Inc.
NEW YORK, Aug. 10, 2020 /PRNewswire/ -- Immunic, Inc.
NEW YORK, Aug. 4, 2020 /PRNewswire/ -- Immunic, Inc.
NEW YORK, Aug. 3, 2020 /PRNewswire/ -- Immunic, Inc.
Immunic, Inc. (IMUX) CEO Daniel Vitt on Q2 2020 Results - Earnings Call Transcript
Immunic Inc (NASDAQ: IMUX) shares are surging following a positive clinical readout.
NEW YORK, July 30, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chroni...
NEW YORK, July 29, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chroni...
NEW YORK, July 27, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chroni...
A cocktail of antiviral agents is more likely than a vaccine (or vaccines) to be effective in treating SARS-CoV-2 infections and preventing COVID-19.
NEW YORK, June 22, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chroni...
NEW YORK, June 15, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chroni...
Immunic (IMUX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Immunic (IMUX) gets a FDA allowance to begin a phase II study on its DHODH inhibitor IMU-838 for addressing COVID-19 in the United States. Top-line results on the same are awaited later this y...
NEW YORK, June 10, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chroni...
NEW YORK, June 9, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic...
NEW YORK, June 9, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic...
NEW YORK, May 29, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic...
NEW YORK, May 19, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic...
About IMUX
Immunic, a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase, which is in Phase 2 clinical development for treatment of ulcerative colitis ... [Read more...]
| Industry Biotechnology | |
| CEO Daniel Vitt | Employees 26 |
| Stock Exchange NASDAQ | Ticker Symbol IMUX |
Analyst Forecasts
According to 6 analysts, the average rating for Immunic stock is "Buy." The 12-month stock price forecast is 60.83, which is an increase of 271.14% from the latest price.